NI-3201 Is a Bispecific Antibody Mediating PD-L1-Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control.

Cancer Immunol Res · 2025 · PMC11876958 · PMID 39760515

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the survival benefit conferred by NI-3201 did not reach statistical significance when compared with atezolizumab, NI-3201 demonstrated a stronger statistical significance than atezolizumab relative to the vehicle control (*** vs. *).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.